Scleroderma is a connective tissue disease with unknown etiology characterized by excessive deposition of extracellular matrix in the skin. Cellular infiltrates of certain immune cells and proinflammatory mediators are suggested to play a crucial role in cutaneous fibrosis, forming complicated networks between fibroblasts and immune cells via cell-cell communications. Tissue-selective trafficking of leukocytes is mediated by combinations of adhesion molecules and chemokines. Recent studies have shown that an increase in proinflammatory chemokines has been associated with the initiation and/or development of skin fibrosis/sclerosis, suggesting that chemokines and their receptors may be important mediators of inflammation and fibrosis in scleroderma. This review will focus on the roles of chemokines and their receptors during the process of cutaneous sclerosis and will also provide a current insight into the potential mechanisms of scleroderma.

1.
Krieg T, Meurer M: Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 1988;18:457–481.
2.
Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E, Krieg T: Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993;100:92–96.
3.
LeRoy EC: Increased collagen synthesis by scleroderma skin fibroblasts in vitro. J Clin Invest 1974;54:880–889.
4.
Krieg T, Perlish JS, Mauch C, Fleischmajer R: Collagen synthesis by scleroderma fibroblasts. Ann NY Acad Sci 1985;460:375–386.
5.
Fleishmajer R, Perlish JS, Reeves JRT: Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977;20:975–984.
6.
Scharffetter K, Lankat-Buttgereit B, Krieg T: Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9–17.
7.
LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM: A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989;32:817–825.
8.
Varga J, Rosenbloom J, Jimenez SA: Transforming growth factor β (TGFβ) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597–604.
9.
Raghow J, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH: Transforming growth factor-β increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987;79:1285–1288.
10.
Ignotz RA, Massague J: Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1988;261:4337–4345.
11.
Heino J, Ignotz RA, Hemler ME, Crouse C, Massague J: Regulation of cell adhesion receptors by transforming growth factor-beta. J Biol Chem 1989;264:380–388.
12.
Ignotz RA, Heino J, Massague J: Regulation of cell adhesion receptors by transforming growth factor-beta. J Biol Chem 1989;264:389–392.
13.
Laiho M, Saksela O, Andreasen PA, Keski-Oja J: Enhanced production and extracellular deposition of the endothelial-type plasminogen activator in cultured human lung fibroblasts by transforming growth factor beta. J Cell Biol 1986;103:2403–2410.
14.
Laiho M, Saksela O, Keski-Oja J: Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987;262:17467–17474.
15.
Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK: Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899–1904.
16.
Obberghen-Schilling EV, Roche NS, Flanders KC, Sporn MB, Roberts AB: Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988;263:7741–7746.
17.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor type β: rapid induction of fibroblasts and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–4171.
18.
Luster AD: Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–445.
19.
Baggiolini M: Chemokines and leukocyte traffic. Nature 1998;392:565–568.
20.
Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121–127.
21.
Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, Murphy PM, Luster AD: Human monocytes chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol 1996;157:5613–5626.
22.
Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129–134.
23.
Lloyd CM, Delaney T, Nguyen T, Tian J, Martinez-A C, Coyle AJ, Gutierrez-Ramos JC: CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp Med 2000;191:265–274.
24.
Kim Y, Sung SS, Kuziel WA, Feldman S, Fu SM, Rose CE Jr: Enhanced airway Th2 responses after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). J Immunol 2001;166:5183–5192.
25.
John AE, Lukacs NW: Chemokines and asthma. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:180–189.
26.
Kovacs EJ: Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991;12:17–23.
27.
Kraling BM, Maul GG, Jemenez SA: Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63:48–56.
28.
Ishikawa O, Ishikawa H: Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992;19:1202–1206.
29.
Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN: Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000;96:4046–4054.
30.
Stumbles PA, Strickland DH, Pimm CL, Proksch SF, Marsh AM, McWiliam AS, Bosco A, Tobagus I, Thomas JA, Napoli S, Proudfoot AE, Wells TN, Holt PG: Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus. J Immunol 2001;17:228–234.
31.
Vecchi A, Massimiliano L, Ramponi S, Luini W, Bernasconi S, Bonocchi R, Allavena P, Parmentier M, Mantovani A, Sozzani S: Differential responsiveness to constitutive vs inducible chemokines of immature and mature mouse dendritic cells. J Leukoc Biol 1999;66:489–494.
32.
Dieu M-C, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373–386.
33.
Gruschwitz M, Sepp N, Kofler H, Wick G: Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology 1991;182:234–255.
34.
Gilmour TK, Wilkinson B, Breit SN, Kossard S: Analysis of dendritic cell populations using a revised histological staging of morphoea. Br J Dermatol 2000;143:1183–1192.
35.
Hawkins RA, Claman HN, Clark RAF, Steigerwald JC: Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985;102:1182–1186.
36.
Nishioka K, Kobayashi Y, Katayama I, Takijiri C: Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987;123:205–208.
37.
Trautmann A, Toksoy A, Engelhardt E, Brocker EB, Gillitzer R: Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-4 in vivo. J Pathol 2000;190:100–106.
38.
Selvan RS, Butterfield JH, Krangel MS: Expression of multiple chemokine genes by human mast cells. J Biol Chem 1994;269:13893–13898.
39.
Moller A, Lippert U, Lessmann D, Kolde G, Hamann K, Welker P, Schadendorf D, Rosenbach T, Luger T, Czarnetzki BM: Human mast cells produce IL-8. J Immunol 1993;151:3261–3266.
40.
Gustafsson R, Fredens K, Nettelbladt O, Hallgren R: Eosinophil activation in systemic sclerosis. Arthritis Rheum 1991;34:414–422.
41.
Zhang K, Flanders KS, Phan SH: Cellular localization of transforming growth factor-β expression in bleomycin-induced pulmonary fibrosis. Am J Pathol 1995;147:352–361.
42.
Pincus SH, Ramesh KS, Wyler DJ: Eosinophils stimulate fibroblast DNA synthesis. Blood 1987;70:572–574.
43.
Birkland TP, Cheavens MD, Pincus SH: Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts. Arch Dermatol Res 1994;286:312–318.
44.
Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA: CCL5 and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992;176:1489–1495.
45.
Terada N, Hamano N, Nomura T, Numata T, Hirai K, Nakajima T, Yamada H, Yoshie O, Ikeda-Ito T, Konno A: Interleukin 13 and tumor necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 2000;30:348–355.
46.
Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M, Hara M, Kamatani N: Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33:2792–2800.
47.
Atamas SP, Luzina IG, Dai H, Wilt SG, White B: Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002;168:1139–1145.
48.
Kaufman J, Sime PJ, Phipps RP: Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol 2004;172:1862–1871.
49.
Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan SY, Roczniak S, Shanafelt AB: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348–27357.
50.
Moore BB, Keane MP, Addison CL, Arenberg DA, Strieter RM: CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Invest Med 1998;46:113–120.
51.
Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-independent angiogenesis. Mol Cell Biol 1997;17:4015–4023.
52.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Fhlert JE, Burdick MD, Strieter RM: CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1–8.
53.
Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morrs SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437–1443.
54.
Distler O, Distler J, Kowal-Bielecka O, Gay RE, Muller-Ladner U, Gay S: Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis. Mod Rheumatol 2002;12:107–112.
55.
Yamamoto T: Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. Clin Exp Rheumatol 2003;21:369–375.
56.
Atamas SP, White B: The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003;15:772–777.
57.
Rollins BJ, Morrison ED, Stiles CD: Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 1988;85:3742–3748.
58.
Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT: Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 1992;89:5371–5375.
59.
Marra F, Defranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P: Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998;152:423–430.
60.
Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH: Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 1994;153:4733–4741.
61.
Lyoid CM, Minto AW, Dorf ME, Proudfoot A, Wells TNC, Salant DJ, Gutierrez-Ramos JC: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescent nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185:1371–1380.
62.
Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779–17784.
63.
Hogaboam CM, Bone-Larson CL, Lipinski S, Lukacs NW, Chensue SW, Strieter RM, Kunkel SL: Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999;163:2193–2201.
64.
Yamamoto T, Nishioka K: Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510–516.
65.
Hasegawa M, Sato S, Takehara K: Augmentation of production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β in patients with systemic sclerosis: MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159–165.
66.
Yamamoto T, Eckes B, Hartmann K, Krieg T: Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133–139.
67.
Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL: Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001;44:1382–1386.
68.
Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Schölmerich J, Michel BA, Gay RE, Matucci-Cerinic M, Gays S, Müller-Landner U: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects of monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665–2678.
69.
Scala E, Palotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O, Puddu P, Paganelli R, Russo G: Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540–546.
70.
Yamamoto T, Eckes B, Krieg T: High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001;31:2936– 2941.
71.
Kuroda K, Shinkai H: Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997;289:567–572.
72.
Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I: The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002;20:221–224.
73.
Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T: Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1α loop. J Immunol 2000;164:6174–6179.
74.
Yamamoto T, Katayama I, Nishioka K: Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology 1998;197:109–114.
75.
Kihira C, Mizutani H, Asahi K, Hamanaka H, Shimizu M: Increased cutaneous immunoreactive stem cell factor expression and serum stem cell factor level in systemic scleroderma. J Dermatol Sci 1999;20:72–78.
76.
Baghestanian M, Hofbauer R, Kiener HP, Bankl HC, Wimazal F, Willheim M, Scheiner O, Fureder W, Muller MR, Bevec D, Lechner K, Valent P: The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood 1997;90:4438–4449.
77.
Yamamoto T, Hartmann K, Eckes B, Krieg T: Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. J Dermatol Sci 2001;26:106–111.
78.
Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479–1485.
79.
Gillery P, Fertin C, Nicolas JF, Chasang F, Kalis B, Banchereau J, Maquart FX: Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 1992;302:231–234.
80.
Sempowski GD, Beckmann MP, Derdak S, Phipps RP: Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994;152:3606–3614.
81.
Needlemann BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1985;28:775–780.
82.
Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL: Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278–285.
83.
Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated levels of interleukin-4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328–332.
84.
Mavilia C, Scaletti C, Romagnani P, Carossino AM, Pignonei A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751–1758.
85.
Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988–994.
86.
Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B: Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998;101:2129–2139.
87.
Jinnin M, Ihn H, Yamane K, Tamaki K: Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004;279:41783–41791.
88.
Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA: IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002;168:2953–2962.
89.
Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, Szeimies RM, Müller-Ladner U, Scholmerich J, Hellerbrand C: The –2518 promoter polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005;124:92–98.
90.
Distler O, Rinkes B, Hohenleutner U, Scholmerich J, Landthaler M, Lang B, Gay S, Müller-Ladner U: Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int 1999;19:39–46.
91.
Anderegg U, Saalbach A, Haustein UF: Chemokine release from activated human dermal microvascular endothelial cells: implications for the pathophysiology of scleroderma? Arch Dermatol Res 2000;292:341–347.
92.
Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP: Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003;48:1979–1991.
93.
Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, Sato S: Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006;65:124–126.
94.
Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, Keane MP: The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004;173:4692–4698.
95.
Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S: Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004;35:43–51.
96.
Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, Trojanowska M, Jimenez SA, White B: Pulmonary and activation-regulated chemokines stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003;29:743–749.
97.
Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S: Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005;52:2889–2896.
98.
Hayakawa I, Hasegawa M, Matsushita T, Yanaba K, Kodera M, Komura K, Takehara K, Sato S: Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology 2005;44:873–878.
99.
Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S: Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003;30:1524–1528.
100.
Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993;61:239–246.
101.
Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:296–301.
102.
Reitamo S, Remitz A, Varga J, Ceska M, Effenbeger F, Jimenez S, Uitto J: Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 1993;129:189–193.
103.
Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, Welsh K, Bunn C, Knight C, Foley P, du Bois RM: Distribution of novel polymorphisms of interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000;168:3088–3098.
104.
Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K: Upregulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005;64:21–28.
105.
Sallusto F, Lanzavecchia A, Mackay CR: Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568–574.
106.
Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM: CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344–345.
107.
Fujii H, Hasegawa M, Takehara K, Mukaida N, Sato S: Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002;130:548–556.
108.
Cerulli MT, Ong VH, Ponticos OM, Shiwen X, Abraham DJ, Black CM, Denton CP: Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772–3782.
109.
Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. 1. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456–462.
110.
Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K: Animal model of sclerotic skin. 2. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 1999;26:2628–2634.
111.
Yamamoto T, Kuroda M, Takagawa S, Nishioka K: Animal model of sclerotic skin. 3. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000;292:535–541.
112.
Yamamoto T, Nishioka K: Animal model of sclerotic skin. 4. Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001;117:999–1001.
113.
Yamamoto T, Nishioka K: Animal model of sclerotic skin. 5. Increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002;102:77–83.
114.
Yamamoto T, Nishioka K: Animal model of sclerotic skin. 6. Evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004;295:453–456.
115.
Yamamoto T, Eckes B, Krieg T: Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 2000;292:556–561.
116.
Takamizawa A, Koyama S, Sato E, Masubuchi T, Kubo K, Sekiguchi M, Nagai S, Izumi T: Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. J Immunol 1999;162:6200–6208.
117.
Casciola-Rosen L, Wigley F, Rosen A: Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997;185:71–79.
118.
Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, Luchetti MM, Gabrielli A: Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999;112:78–84.
119.
Yamamoto T, Takagawa S, Mizushima Y, Nishioka K: Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999;113:843–847.
120.
Galindo M, Santiago B, Alcami J, Rivero M, Martin-Serrano J, Pablos JL: Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001;123:36–41.
121.
Jaffee BD, Claman HN: Chronic graft-versus-host disease (GVHD) as a model for scleroderma. 1. Description of model system. Cell Immunol 1983;73:1–12.
122.
Claman HN, Jaffee BD, Huff JC, Clark RAF: Chronic graft-versus-host disease as a model for scleroderma. 2. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985;94:73–84.
123.
McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693–5699.
124.
Zhang Y, Mccormick LL, Desai SR, Wu S, Gilliam AC: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088–3098.
125.
MacGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Rα and transforming growth factor-β genes. J Invest Dermatol 2001;116:136–143.
126.
Ong CJ, Ip S, Teh SJ, Wong C, Jirik FR, Grusby M, Teh HS: A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999;196:60–68.
127.
Pablos JL, Everett ET, Harley R, LeRoy EC, Norris JS: Transforming growth factor-β1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995;72:670–678.
128.
Wang H-W, Tedla N, Hunt JE, Wakefield D, McNeil HP: Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005;14:295–302.
129.
Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA: Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993;6:701–718.
130.
Ong CJ, Ip S, Teh SJ, Wong C, Jirik FR, Grusby M, Teh HS: A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999;196:60–68.
131.
Wallace VA, Kondo S, Kono T, Xing Z, Timms E, Furlonger C, Keystone E, Gauldie J, Sauder DN, Mak TW, Paige CJ: A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994;24:1463–1466.
132.
Walker M, Harley R, LeRoy EC: Inhibition of fibrosis in Tsk mice by blocking mast cell degranulation. J Rheumatol 1987;14:299–301.
133.
Walker M, Harley R, LeRoy EC: Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 1990;17:57–59.
134.
Kikuchi H, Hanazawa S, Takeshita A, Nakada Y, Yamashita Y, Kitano S: Interleukin-4 acts as a potent stimulator for expression of monocyte chemoattractant JE/MCP-1 in mouse peritoneal macrophages. Biochem Biophys Res Commun 1993;203:562–569.
135.
Lee YW, Hennig B, Toborek M: Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 2003;284:H185–H192.
136.
Lukacs NW, Chensue SW, Karpus WJ, Lincoln P, Keefer C, Strieter RM, Kunkel SL: C-C chemokines differentially alter interleukin-4 production from lymphocytes. Am J Pathol 1997;150:1861–1868.
137.
Shinozaki M, Kawara S, Hayashi N, Kakinuma T, Igarashi A, Takehara K: Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor-beta-simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997;237:292–297.
138.
Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K: Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999;181:153–159.
139.
Takehara K: Pathogenesis of systemic sclerosis. J Rheumatol 2003:30:755–759.
140.
Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, Takigawa M, Takehara K: Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2005;203:447–456.
141.
Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, Takeshita A, Kitamoto S, Egashira K, Hara N: Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Cell Moll Physiol 2004;286:L1038–L1044.
142.
Moore BB, Paine R III, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB: Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001;167:4368–4377.
143.
Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH: C-C chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 2003;24:266–276.
144.
Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, Takeya M: C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004;204:594–604.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.